May 22 (Reuters) – Lantheus Holdings is weighing a potential sale after getting a takeover offer from private-equity backed Curium Pharma that values it at about $7 billion, Bloomberg News reported on Friday, citing people familiar with the matter.
The two companies have been in discussions about a potential deal that could be weeks away, the report said, adding that no final decision has been made and there is no guarantee the talks will result in a transaction.
Curium was valued at about $7 billion last year when its owner, CapVest Partners, raised funds for a continuation vehicle for the nuclear medicine company, the report said.
Lantheus and Curium did not immediately respond to Reuters’ request for comment.
Shares of the radiopharmaceutical-focused company were trading down nearly 2% in extended trading. They have gained 54.8% so far this year, giving the company a market capitalization of about $6.15 billion.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Shilpi Majumdar)
